Like for opioids, there will be a need for educating patients and family about the risks and benefits of cannabis-based medicines. Equally, there will be a need to moderate expectations about cannabis-based medicines, given the media hype about them being a ‘panacea’.
Like in the Netherlands in early 2000’s, Thailand is approaching this matter from an objective, scientific basis. The health and wellbeing of the population are dominant concerns. Making cannabis-based medicines affordable is also essential. The GPO is responsible for delivering essential medicines to the population at an affordable price. It is likely that the GPO will also lead the advancement of cannabis-based medicines for Thailand.
Thailand is a respected thought leader in the ASEAN community. It is likely that neighbouring countries will watch the developments closely as Thailand progresses toward the re-introduction of cannabis-based medicines.